查看購物車
  • Simplified Chinese
  • English
  • Japanese
  • Korean
封面
市場調查報告書
商品編碼
1231660

伴隨診斷的全球市場

Companion Diagnostics
出版日期: | 出版商: Global Industry Analysts, Inc. | 英文 196 Pages | 商品交期: 最快1-2個工作天內

價格

※ 本網頁內容可能與最新版本有所差異。詳細情況請與我們聯繫。

簡介目錄

伴隨診斷的全球市場到2030年將達到138億美元

在COVID-19後改變的商務環境中，2022年79億美元的伴隨診斷的全球市場，2030年之前達到138億美元規模，在2022年～2030年預計將以年複合成長率7.2％增長。本報告所分析之市場區隔之一的化驗套件及試劑將記錄年複合成長率6.3％，到分析期間結束時達到87億美元。考慮疫情後的復甦，軟體&服務領域今後8年的年複合成長率將修正為9.1％。

美國市場估算為23億美元，中國則將以年複合成長率6.7％的速度成長預測

美國的伴隨診斷市場在2022年估算為23億美元。作為世界第2大經濟大國的中國，在2022年～2030年預計將以年複合成長率6.7％推移，2030年達到24億美元的市場規模。其他熱門的地區市場有日本和加拿大，在2022年～2030年預計將各以4.8％和4.3％的速度成長。在歐洲市場中，德國預計將以年複合成長率2.3％成長。

調查對像企業範例

  • Abbott Molecular
  • Agilent Technologies, Inc.
  • bioMerieux SA
  • Cepheid
  • Danaher Corporation
  • F. Hoffmann-La Roche Ltd.
  • Foundation Medicine Inc.
  • Laboratory Corporation of America(R)Holdings
  • Leica Biosystems Nussloch GmbH
  • Merck & Co. Inc.
  • Myriad Genetics Inc.
  • NeoGenomics Laboratories, Inc.
  • QIAGEN N.V.
  • Quest Diagnostics Inc.
  • Thermo Fischer Scientific Inc.

目錄

第1章 調查手法

第2章 摘要整理

  • 市場概要
  • 主要企業
  • 市場趨勢與推動因素
  • 全球市場預測

第3章 市場分析

  • 美國
  • 加拿大
  • 日本
  • 中國
  • 歐洲
  • 法國
  • 德國
  • 義大利
  • 英國
  • 其他歐洲
  • 亞太地區
  • 全球其他地區

第4章 競爭

簡介目錄
Product Code: MCP-6736

What`s New for 2023?

»Special coverage on Russia-Ukraine war; global inflation; easing of "zero-Covid" policy in China and its `bumpy` reopening; supply chain disruptions, global trade tensions; and risk of recession.

»Global competitiveness and key competitor percentage market shares

» Market presence across multiple geographies - Strong/Active/Niche/Trivial

»Online interactive peer-to-peer collaborative bespoke updates

»Access to our digital archives and MarketGlass Research Platform

»Complimentary updates for one year

Looking Ahead to 2023

The global economy is at a critical crossroads with a number of interlocking challenges and crises running in parallel. The uncertainty around how Russia`s war on Ukraine will play out this year and the war`s role in creating global instability means that the trouble on the inflation front is not over yet. Food and fuel inflation will remain a persistent economic problem. Higher retail inflation will impact consumer confidence and spending. As governments combat inflation by raising interest rates, new job creation will slowdown and impact economic activity and growth. Lower capital expenditure is in the offing as companies go slow on investments, held back by inflation worries and weaker demand. With slower growth and high inflation, developed markets seem primed to enter into a recession. Fears of new COVID outbreaks and China's already uncertain post-pandemic path poses a real risk of the world experiencing more acute supply chain pain and manufacturing disruptions this year. Volatile financial markets, growing trade tensions, stricter regulatory environment and pressure to mainstream climate change into economic decisions will compound the complexity of challenges faced. Year 2023 is expected to be tough year for most markets, investors and consumers. Nevertheless, there is always opportunity for businesses and their leaders who can chart a path forward with resilience and adaptability.

Global Companion Diagnostics Market to Reach $13.8 Billion by 2030

In the changed post COVID-19 business landscape, the global market for Companion Diagnostics estimated at US$7.9 Billion in the year 2022, is projected to reach a revised size of US$13.8 Billion by 2030, growing at aCAGR of 7.2% over the period 2022-2030. Assay kits & Reagents, one of the segments analyzed in the report, is projected to record 6.3% CAGR and reach US$8.7 Billion by the end of the analysis period. Taking into account the ongoing post pandemic recovery, growth in the Software & Services segment is readjusted to a revised 9.1% CAGR for the next 8-year period.

The U.S. Market is Estimated at $2.3 Billion, While China is Forecast to Grow at 6.7% CAGR

The Companion Diagnostics market in the U.S. is estimated at US$2.3 Billion in the year 2022. China, the world`s second largest economy, is forecast to reach a projected market size of US$2.4 Billion by the year 2030 trailing a CAGR of 6.7% over the analysis period 2022 to 2030. Among the other noteworthy geographic markets are Japan and Canada, each forecast to grow at 4.8% and 4.3% respectively over the 2022-2030 period. Within Europe, Germany is forecast to grow at approximately 2.3% CAGR.

Select Competitors (Total 47 Featured):

  • Abbott Molecular
  • Agilent Technologies, Inc.
  • bioMerieux SA
  • Cepheid
  • Danaher Corporation
  • F. Hoffmann-La Roche Ltd.
  • Foundation Medicine Inc.
  • Laboratory Corporation of America® Holdings
  • Leica Biosystems Nussloch GmbH
  • Merck & Co. Inc.
  • Myriad Genetics Inc.
  • NeoGenomics Laboratories, Inc.
  • QIAGEN N.V.
  • Quest Diagnostics Inc.
  • Thermo Fischer Scientific Inc.

TABLE OF CONTENTS

I. METHODOLOGY

II. EXECUTIVE SUMMARY

  • 1. MARKET OVERVIEW
    • Influencer Market Insights
    • World Market Trajectories
    • Impact of Covid-19 and a Looming Global Recession
    • Companion Diagnostics: An Introductory Prelude
    • Quashing the One-Size-Fits-All Approach, CDx Wield Great Promise for Streamlined Drug Discovery & Development
    • Broader Scope and Applications Rev Up Growth Opportunities
    • Healthy Growth Projected over the Next Few Years
    • Developed Regions: Key Revenue Contributors
    • Market Witnesses Fast Paced Growth in Developing Regions
    • Northbound Trajectory in R&D Spending Creates Conducive Environment
    • Prevailing Economic Scenario Favors Funding Pattern
    • Companion Diagnostics - Global Key Competitors Percentage Market Share in 2022 (E)
    • Competitive Market Presence - Strong/Active/Niche/Trivial for Players Worldwide in 2022 (E)
  • 2. FOCUS ON SELECT PLAYERS
  • 3. MARKET TRENDS & DRIVERS
    • Growing Significance of Personalized Medicine Remains a Major Market Driver
    • Emphasis on Improving Targeted Therapies with CDx Tests Steers Momentum
    • Herceptin Lays the Road for Companion Diagnostics
    • Oncology - Dominant Therapy Area for CDx
    • Rising Incidence of Cancer Propels the Need for CDx Tests
    • Technology Advancements to Widen CDx Use Case
    • PCR: Dominant Technology Type for CDx Testing
    • Next-Generation Sequencing (NGS) Gains Widespread Traction in CDx Testing
    • Significant Role of Biomarkers in Companion Diagnostics
    • Critical Healthcare Needs of Aging Population Underpin CDx Sales
    • Regulatory Scenario Favors CDx Market
    • Resolving Prevailing Challenges: Critical for Future Growth of CDx Market
  • 4. GLOBAL MARKET PERSPECTIVE
    • TABLE 1: World Recent Past, Current & Future Analysis for Companion Diagnostics by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Million for Years 2022 through 2030 and % CAGR
    • TABLE 2: World 8-Year Perspective for Companion Diagnostics by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets for Years 2023 & 2030
    • TABLE 3: World Recent Past, Current & Future Analysis for Assay kits & Reagents by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Million for Years 2022 through 2030 and % CAGR
    • TABLE 4: World 8-Year Perspective for Assay kits & Reagents by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World for Years 2023 & 2030
    • TABLE 5: World Recent Past, Current & Future Analysis for Software & Services by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Million for Years 2022 through 2030 and % CAGR
    • TABLE 6: World 8-Year Perspective for Software & Services by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World for Years 2023 & 2030
    • TABLE 7: World Recent Past, Current & Future Analysis for Polymerase Chain Reaction (PCR) by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Million for Years 2022 through 2030 and % CAGR
    • TABLE 8: World 8-Year Perspective for Polymerase Chain Reaction (PCR) by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World for Years 2023 & 2030
    • TABLE 9: World Recent Past, Current & Future Analysis for Immunohistochemistry (IHC) by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Million for Years 2022 through 2030 and % CAGR
    • TABLE 10: World 8-Year Perspective for Immunohistochemistry (IHC) by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World for Years 2023 & 2030
    • TABLE 11: World Recent Past, Current & Future Analysis for In Situ Hybridization (ISH) by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Million for Years 2022 through 2030 and % CAGR
    • TABLE 12: World 8-Year Perspective for In Situ Hybridization (ISH) by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World for Years 2023 & 2030
    • TABLE 13: World Recent Past, Current & Future Analysis for Next-Generation Sequencing (NGS) by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Million for Years 2022 through 2030 and % CAGR
    • TABLE 14: World 8-Year Perspective for Next-Generation Sequencing (NGS) by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World for Years 2023 & 2030
    • TABLE 15: World Recent Past, Current & Future Analysis for Other Technologies by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Million for Years 2022 through 2030 and % CAGR
    • TABLE 16: World 8-Year Perspective for Other Technologies by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World for Years 2023 & 2030
    • TABLE 17: World Recent Past, Current & Future Analysis for Oncology by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Million for Years 2022 through 2030 and % CAGR
    • TABLE 18: World 8-Year Perspective for Oncology by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World for Years 2023 & 2030
    • TABLE 19: World Recent Past, Current & Future Analysis for Neurology by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Million for Years 2022 through 2030 and % CAGR
    • TABLE 20: World 8-Year Perspective for Neurology by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World for Years 2023 & 2030
    • TABLE 21: World Recent Past, Current & Future Analysis for Other Indications by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Million for Years 2022 through 2030 and % CAGR
    • TABLE 22: World 8-Year Perspective for Other Indications by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World for Years 2023 & 2030
    • TABLE 23: World Recent Past, Current & Future Analysis for Pharmaceutical & Biopharmaceutical Companies by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Million for Years 2022 through 2030 and % CAGR
    • TABLE 24: World 8-Year Perspective for Pharmaceutical & Biopharmaceutical Companies by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World for Years 2023 & 2030
    • TABLE 25: World Recent Past, Current & Future Analysis for Reference Laboratories by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Million for Years 2022 through 2030 and % CAGR
    • TABLE 26: World 8-Year Perspective for Reference Laboratories by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World for Years 2023 & 2030
    • TABLE 27: World Recent Past, Current & Future Analysis for CROs by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Million for Years 2022 through 2030 and % CAGR
    • TABLE 28: World 8-Year Perspective for CROs by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World for Years 2023 & 2030
    • TABLE 29: World Recent Past, Current & Future Analysis for Other End-Uses by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Million for Years 2022 through 2030 and % CAGR
    • TABLE 30: World 8-Year Perspective for Other End-Uses by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World for Years 2023 & 2030
    • TABLE 31: World Companion Diagnostics Market Analysis of Annual Sales in US$ Million for Years 2014 through 2030

III. MARKET ANALYSIS

  • UNITED STATES
    • Companion Diagnostics Market Presence - Strong/Active/Niche/Trivial - Key Competitors in the United States for 2023 (E)
    • TABLE 32: USA Recent Past, Current & Future Analysis for Companion Diagnostics by Product & Service - Assay kits & Reagents and Software & Services - Independent Analysis of Annual Sales in US$ Million for the Years 2022 through 2030 and % CAGR
    • TABLE 33: USA 8-Year Perspective for Companion Diagnostics by Product & Service - Percentage Breakdown of Value Sales for Assay kits & Reagents and Software & Services for the Years 2023 & 2030
    • TABLE 34: USA Recent Past, Current & Future Analysis for Companion Diagnostics by Technology - Polymerase Chain Reaction (PCR), Immunohistochemistry (IHC), In Situ Hybridization (ISH), Next-Generation Sequencing (NGS) and Other Technologies - Independent Analysis of Annual Sales in US$ Million for the Years 2022 through 2030 and % CAGR
    • TABLE 35: USA 8-Year Perspective for Companion Diagnostics by Technology - Percentage Breakdown of Value Sales for Polymerase Chain Reaction (PCR), Immunohistochemistry (IHC), In Situ Hybridization (ISH), Next-Generation Sequencing (NGS) and Other Technologies for the Years 2023 & 2030
    • TABLE 36: USA Recent Past, Current & Future Analysis for Companion Diagnostics by Indication - Oncology, Neurology and Other Indications - Independent Analysis of Annual Sales in US$ Million for the Years 2022 through 2030 and % CAGR
    • TABLE 37: USA 8-Year Perspective for Companion Diagnostics by Indication - Percentage Breakdown of Value Sales for Oncology, Neurology and Other Indications for the Years 2023 & 2030
    • TABLE 38: USA Recent Past, Current & Future Analysis for Companion Diagnostics by End-Use - Pharmaceutical & Biopharmaceutical Companies, Reference Laboratories, CROs and Other End-Uses - Independent Analysis of Annual Sales in US$ Million for the Years 2022 through 2030 and % CAGR
    • TABLE 39: USA 8-Year Perspective for Companion Diagnostics by End-Use - Percentage Breakdown of Value Sales for Pharmaceutical & Biopharmaceutical Companies, Reference Laboratories, CROs and Other End-Uses for the Years 2023 & 2030
  • CANADA
    • TABLE 40: Canada Recent Past, Current & Future Analysis for Companion Diagnostics by Product & Service - Assay kits & Reagents and Software & Services - Independent Analysis of Annual Sales in US$ Million for the Years 2022 through 2030 and % CAGR
    • TABLE 41: Canada 8-Year Perspective for Companion Diagnostics by Product & Service - Percentage Breakdown of Value Sales for Assay kits & Reagents and Software & Services for the Years 2023 & 2030
    • TABLE 42: Canada Recent Past, Current & Future Analysis for Companion Diagnostics by Technology - Polymerase Chain Reaction (PCR), Immunohistochemistry (IHC), In Situ Hybridization (ISH), Next-Generation Sequencing (NGS) and Other Technologies - Independent Analysis of Annual Sales in US$ Million for the Years 2022 through 2030 and % CAGR
    • TABLE 43: Canada 8-Year Perspective for Companion Diagnostics by Technology - Percentage Breakdown of Value Sales for Polymerase Chain Reaction (PCR), Immunohistochemistry (IHC), In Situ Hybridization (ISH), Next-Generation Sequencing (NGS) and Other Technologies for the Years 2023 & 2030
    • TABLE 44: Canada Recent Past, Current & Future Analysis for Companion Diagnostics by Indication - Oncology, Neurology and Other Indications - Independent Analysis of Annual Sales in US$ Million for the Years 2022 through 2030 and % CAGR
    • TABLE 45: Canada 8-Year Perspective for Companion Diagnostics by Indication - Percentage Breakdown of Value Sales for Oncology, Neurology and Other Indications for the Years 2023 & 2030
    • TABLE 46: Canada Recent Past, Current & Future Analysis for Companion Diagnostics by End-Use - Pharmaceutical & Biopharmaceutical Companies, Reference Laboratories, CROs and Other End-Uses - Independent Analysis of Annual Sales in US$ Million for the Years 2022 through 2030 and % CAGR
    • TABLE 47: Canada 8-Year Perspective for Companion Diagnostics by End-Use - Percentage Breakdown of Value Sales for Pharmaceutical & Biopharmaceutical Companies, Reference Laboratories, CROs and Other End-Uses for the Years 2023 & 2030
  • JAPAN
    • Companion Diagnostics Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Japan for 2023 (E)
    • TABLE 48: Japan Recent Past, Current & Future Analysis for Companion Diagnostics by Product & Service - Assay kits & Reagents and Software & Services - Independent Analysis of Annual Sales in US$ Million for the Years 2022 through 2030 and % CAGR
    • TABLE 49: Japan 8-Year Perspective for Companion Diagnostics by Product & Service - Percentage Breakdown of Value Sales for Assay kits & Reagents and Software & Services for the Years 2023 & 2030
    • TABLE 50: Japan Recent Past, Current & Future Analysis for Companion Diagnostics by Technology - Polymerase Chain Reaction (PCR), Immunohistochemistry (IHC), In Situ Hybridization (ISH), Next-Generation Sequencing (NGS) and Other Technologies - Independent Analysis of Annual Sales in US$ Million for the Years 2022 through 2030 and % CAGR
    • TABLE 51: Japan 8-Year Perspective for Companion Diagnostics by Technology - Percentage Breakdown of Value Sales for Polymerase Chain Reaction (PCR), Immunohistochemistry (IHC), In Situ Hybridization (ISH), Next-Generation Sequencing (NGS) and Other Technologies for the Years 2023 & 2030
    • TABLE 52: Japan Recent Past, Current & Future Analysis for Companion Diagnostics by Indication - Oncology, Neurology and Other Indications - Independent Analysis of Annual Sales in US$ Million for the Years 2022 through 2030 and % CAGR
    • TABLE 53: Japan 8-Year Perspective for Companion Diagnostics by Indication - Percentage Breakdown of Value Sales for Oncology, Neurology and Other Indications for the Years 2023 & 2030
    • TABLE 54: Japan Recent Past, Current & Future Analysis for Companion Diagnostics by End-Use - Pharmaceutical & Biopharmaceutical Companies, Reference Laboratories, CROs and Other End-Uses - Independent Analysis of Annual Sales in US$ Million for the Years 2022 through 2030 and % CAGR
    • TABLE 55: Japan 8-Year Perspective for Companion Diagnostics by End-Use - Percentage Breakdown of Value Sales for Pharmaceutical & Biopharmaceutical Companies, Reference Laboratories, CROs and Other End-Uses for the Years 2023 & 2030
  • CHINA
    • Companion Diagnostics Market Presence - Strong/Active/Niche/Trivial - Key Competitors in China for 2023 (E)
    • TABLE 56: China Recent Past, Current & Future Analysis for Companion Diagnostics by Product & Service - Assay kits & Reagents and Software & Services - Independent Analysis of Annual Sales in US$ Million for the Years 2022 through 2030 and % CAGR
    • TABLE 57: China 8-Year Perspective for Companion Diagnostics by Product & Service - Percentage Breakdown of Value Sales for Assay kits & Reagents and Software & Services for the Years 2023 & 2030
    • TABLE 58: China Recent Past, Current & Future Analysis for Companion Diagnostics by Technology - Polymerase Chain Reaction (PCR), Immunohistochemistry (IHC), In Situ Hybridization (ISH), Next-Generation Sequencing (NGS) and Other Technologies - Independent Analysis of Annual Sales in US$ Million for the Years 2022 through 2030 and % CAGR
    • TABLE 59: China 8-Year Perspective for Companion Diagnostics by Technology - Percentage Breakdown of Value Sales for Polymerase Chain Reaction (PCR), Immunohistochemistry (IHC), In Situ Hybridization (ISH), Next-Generation Sequencing (NGS) and Other Technologies for the Years 2023 & 2030
    • TABLE 60: China Recent Past, Current & Future Analysis for Companion Diagnostics by Indication - Oncology, Neurology and Other Indications - Independent Analysis of Annual Sales in US$ Million for the Years 2022 through 2030 and % CAGR
    • TABLE 61: China 8-Year Perspective for Companion Diagnostics by Indication - Percentage Breakdown of Value Sales for Oncology, Neurology and Other Indications for the Years 2023 & 2030
    • TABLE 62: China Recent Past, Current & Future Analysis for Companion Diagnostics by End-Use - Pharmaceutical & Biopharmaceutical Companies, Reference Laboratories, CROs and Other End-Uses - Independent Analysis of Annual Sales in US$ Million for the Years 2022 through 2030 and % CAGR
    • TABLE 63: China 8-Year Perspective for Companion Diagnostics by End-Use - Percentage Breakdown of Value Sales for Pharmaceutical & Biopharmaceutical Companies, Reference Laboratories, CROs and Other End-Uses for the Years 2023 & 2030
  • EUROPE
    • Companion Diagnostics Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Europe for 2023 (E)
    • TABLE 64: Europe Recent Past, Current & Future Analysis for Companion Diagnostics by Geographic Region - France, Germany, Italy, UK and Rest of Europe Markets - Independent Analysis of Annual Sales in US$ Million for Years 2022 through 2030 and % CAGR
    • TABLE 65: Europe 8-Year Perspective for Companion Diagnostics by Geographic Region - Percentage Breakdown of Value Sales for France, Germany, Italy, UK and Rest of Europe Markets for Years 2023 & 2030
    • TABLE 66: Europe Recent Past, Current & Future Analysis for Companion Diagnostics by Product & Service - Assay kits & Reagents and Software & Services - Independent Analysis of Annual Sales in US$ Million for the Years 2022 through 2030 and % CAGR
    • TABLE 67: Europe 8-Year Perspective for Companion Diagnostics by Product & Service - Percentage Breakdown of Value Sales for Assay kits & Reagents and Software & Services for the Years 2023 & 2030
    • TABLE 68: Europe Recent Past, Current & Future Analysis for Companion Diagnostics by Technology - Polymerase Chain Reaction (PCR), Immunohistochemistry (IHC), In Situ Hybridization (ISH), Next-Generation Sequencing (NGS) and Other Technologies - Independent Analysis of Annual Sales in US$ Million for the Years 2022 through 2030 and % CAGR
    • TABLE 69: Europe 8-Year Perspective for Companion Diagnostics by Technology - Percentage Breakdown of Value Sales for Polymerase Chain Reaction (PCR), Immunohistochemistry (IHC), In Situ Hybridization (ISH), Next-Generation Sequencing (NGS) and Other Technologies for the Years 2023 & 2030
    • TABLE 70: Europe Recent Past, Current & Future Analysis for Companion Diagnostics by Indication - Oncology, Neurology and Other Indications - Independent Analysis of Annual Sales in US$ Million for the Years 2022 through 2030 and % CAGR
    • TABLE 71: Europe 8-Year Perspective for Companion Diagnostics by Indication - Percentage Breakdown of Value Sales for Oncology, Neurology and Other Indications for the Years 2023 & 2030
    • TABLE 72: Europe Recent Past, Current & Future Analysis for Companion Diagnostics by End-Use - Pharmaceutical & Biopharmaceutical Companies, Reference Laboratories, CROs and Other End-Uses - Independent Analysis of Annual Sales in US$ Million for the Years 2022 through 2030 and % CAGR
    • TABLE 73: Europe 8-Year Perspective for Companion Diagnostics by End-Use - Percentage Breakdown of Value Sales for Pharmaceutical & Biopharmaceutical Companies, Reference Laboratories, CROs and Other End-Uses for the Years 2023 & 2030
  • FRANCE
    • Companion Diagnostics Market Presence - Strong/Active/Niche/Trivial - Key Competitors in France for 2023 (E)
    • TABLE 74: France Recent Past, Current & Future Analysis for Companion Diagnostics by Product & Service - Assay kits & Reagents and Software & Services - Independent Analysis of Annual Sales in US$ Million for the Years 2022 through 2030 and % CAGR
    • TABLE 75: France 8-Year Perspective for Companion Diagnostics by Product & Service - Percentage Breakdown of Value Sales for Assay kits & Reagents and Software & Services for the Years 2023 & 2030
    • TABLE 76: France Recent Past, Current & Future Analysis for Companion Diagnostics by Technology - Polymerase Chain Reaction (PCR), Immunohistochemistry (IHC), In Situ Hybridization (ISH), Next-Generation Sequencing (NGS) and Other Technologies - Independent Analysis of Annual Sales in US$ Million for the Years 2022 through 2030 and % CAGR
    • TABLE 77: France 8-Year Perspective for Companion Diagnostics by Technology - Percentage Breakdown of Value Sales for Polymerase Chain Reaction (PCR), Immunohistochemistry (IHC), In Situ Hybridization (ISH), Next-Generation Sequencing (NGS) and Other Technologies for the Years 2023 & 2030
    • TABLE 78: France Recent Past, Current & Future Analysis for Companion Diagnostics by Indication - Oncology, Neurology and Other Indications - Independent Analysis of Annual Sales in US$ Million for the Years 2022 through 2030 and % CAGR
    • TABLE 79: France 8-Year Perspective for Companion Diagnostics by Indication - Percentage Breakdown of Value Sales for Oncology, Neurology and Other Indications for the Years 2023 & 2030
    • TABLE 80: France Recent Past, Current & Future Analysis for Companion Diagnostics by End-Use - Pharmaceutical & Biopharmaceutical Companies, Reference Laboratories, CROs and Other End-Uses - Independent Analysis of Annual Sales in US$ Million for the Years 2022 through 2030 and % CAGR
    • TABLE 81: France 8-Year Perspective for Companion Diagnostics by End-Use - Percentage Breakdown of Value Sales for Pharmaceutical & Biopharmaceutical Companies, Reference Laboratories, CROs and Other End-Uses for the Years 2023 & 2030
  • GERMANY
    • Companion Diagnostics Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Germany for 2023 (E)
    • TABLE 82: Germany Recent Past, Current & Future Analysis for Companion Diagnostics by Product & Service - Assay kits & Reagents and Software & Services - Independent Analysis of Annual Sales in US$ Million for the Years 2022 through 2030 and % CAGR
    • TABLE 83: Germany 8-Year Perspective for Companion Diagnostics by Product & Service - Percentage Breakdown of Value Sales for Assay kits & Reagents and Software & Services for the Years 2023 & 2030
    • TABLE 84: Germany Recent Past, Current & Future Analysis for Companion Diagnostics by Technology - Polymerase Chain Reaction (PCR), Immunohistochemistry (IHC), In Situ Hybridization (ISH), Next-Generation Sequencing (NGS) and Other Technologies - Independent Analysis of Annual Sales in US$ Million for the Years 2022 through 2030 and % CAGR
    • TABLE 85: Germany 8-Year Perspective for Companion Diagnostics by Technology - Percentage Breakdown of Value Sales for Polymerase Chain Reaction (PCR), Immunohistochemistry (IHC), In Situ Hybridization (ISH), Next-Generation Sequencing (NGS) and Other Technologies for the Years 2023 & 2030
    • TABLE 86: Germany Recent Past, Current & Future Analysis for Companion Diagnostics by Indication - Oncology, Neurology and Other Indications - Independent Analysis of Annual Sales in US$ Million for the Years 2022 through 2030 and % CAGR
    • TABLE 87: Germany 8-Year Perspective for Companion Diagnostics by Indication - Percentage Breakdown of Value Sales for Oncology, Neurology and Other Indications for the Years 2023 & 2030
    • TABLE 88: Germany Recent Past, Current & Future Analysis for Companion Diagnostics by End-Use - Pharmaceutical & Biopharmaceutical Companies, Reference Laboratories, CROs and Other End-Uses - Independent Analysis of Annual Sales in US$ Million for the Years 2022 through 2030 and % CAGR
    • TABLE 89: Germany 8-Year Perspective for Companion Diagnostics by End-Use - Percentage Breakdown of Value Sales for Pharmaceutical & Biopharmaceutical Companies, Reference Laboratories, CROs and Other End-Uses for the Years 2023 & 2030
  • ITALY
    • TABLE 90: Italy Recent Past, Current & Future Analysis for Companion Diagnostics by Product & Service - Assay kits & Reagents and Software & Services - Independent Analysis of Annual Sales in US$ Million for the Years 2022 through 2030 and % CAGR
    • TABLE 91: Italy 8-Year Perspective for Companion Diagnostics by Product & Service - Percentage Breakdown of Value Sales for Assay kits & Reagents and Software & Services for the Years 2023 & 2030
    • TABLE 92: Italy Recent Past, Current & Future Analysis for Companion Diagnostics by Technology - Polymerase Chain Reaction (PCR), Immunohistochemistry (IHC), In Situ Hybridization (ISH), Next-Generation Sequencing (NGS) and Other Technologies - Independent Analysis of Annual Sales in US$ Million for the Years 2022 through 2030 and % CAGR
    • TABLE 93: Italy 8-Year Perspective for Companion Diagnostics by Technology - Percentage Breakdown of Value Sales for Polymerase Chain Reaction (PCR), Immunohistochemistry (IHC), In Situ Hybridization (ISH), Next-Generation Sequencing (NGS) and Other Technologies for the Years 2023 & 2030
    • TABLE 94: Italy Recent Past, Current & Future Analysis for Companion Diagnostics by Indication - Oncology, Neurology and Other Indications - Independent Analysis of Annual Sales in US$ Million for the Years 2022 through 2030 and % CAGR
    • TABLE 95: Italy 8-Year Perspective for Companion Diagnostics by Indication - Percentage Breakdown of Value Sales for Oncology, Neurology and Other Indications for the Years 2023 & 2030
    • TABLE 96: Italy Recent Past, Current & Future Analysis for Companion Diagnostics by End-Use - Pharmaceutical & Biopharmaceutical Companies, Reference Laboratories, CROs and Other End-Uses - Independent Analysis of Annual Sales in US$ Million for the Years 2022 through 2030 and % CAGR
    • TABLE 97: Italy 8-Year Perspective for Companion Diagnostics by End-Use - Percentage Breakdown of Value Sales for Pharmaceutical & Biopharmaceutical Companies, Reference Laboratories, CROs and Other End-Uses for the Years 2023 & 2030
  • UNITED KINGDOM
    • Companion Diagnostics Market Presence - Strong/Active/Niche/Trivial - Key Competitors in the United Kingdom for 2023 (E)
    • TABLE 98: UK Recent Past, Current & Future Analysis for Companion Diagnostics by Product & Service - Assay kits & Reagents and Software & Services - Independent Analysis of Annual Sales in US$ Million for the Years 2022 through 2030 and % CAGR
    • TABLE 99: UK 8-Year Perspective for Companion Diagnostics by Product & Service - Percentage Breakdown of Value Sales for Assay kits & Reagents and Software & Services for the Years 2023 & 2030
    • TABLE 100: UK Recent Past, Current & Future Analysis for Companion Diagnostics by Technology - Polymerase Chain Reaction (PCR), Immunohistochemistry (IHC), In Situ Hybridization (ISH), Next-Generation Sequencing (NGS) and Other Technologies - Independent Analysis of Annual Sales in US$ Million for the Years 2022 through 2030 and % CAGR
    • TABLE 101: UK 8-Year Perspective for Companion Diagnostics by Technology - Percentage Breakdown of Value Sales for Polymerase Chain Reaction (PCR), Immunohistochemistry (IHC), In Situ Hybridization (ISH), Next-Generation Sequencing (NGS) and Other Technologies for the Years 2023 & 2030
    • TABLE 102: UK Recent Past, Current & Future Analysis for Companion Diagnostics by Indication - Oncology, Neurology and Other Indications - Independent Analysis of Annual Sales in US$ Million for the Years 2022 through 2030 and % CAGR
    • TABLE 103: UK 8-Year Perspective for Companion Diagnostics by Indication - Percentage Breakdown of Value Sales for Oncology, Neurology and Other Indications for the Years 2023 & 2030
    • TABLE 104: UK Recent Past, Current & Future Analysis for Companion Diagnostics by End-Use - Pharmaceutical & Biopharmaceutical Companies, Reference Laboratories, CROs and Other End-Uses - Independent Analysis of Annual Sales in US$ Million for the Years 2022 through 2030 and % CAGR
    • TABLE 105: UK 8-Year Perspective for Companion Diagnostics by End-Use - Percentage Breakdown of Value Sales for Pharmaceutical & Biopharmaceutical Companies, Reference Laboratories, CROs and Other End-Uses for the Years 2023 & 2030
  • REST OF EUROPE
    • TABLE 106: Rest of Europe Recent Past, Current & Future Analysis for Companion Diagnostics by Product & Service - Assay kits & Reagents and Software & Services - Independent Analysis of Annual Sales in US$ Million for the Years 2022 through 2030 and % CAGR
    • TABLE 107: Rest of Europe 8-Year Perspective for Companion Diagnostics by Product & Service - Percentage Breakdown of Value Sales for Assay kits & Reagents and Software & Services for the Years 2023 & 2030
    • TABLE 108: Rest of Europe Recent Past, Current & Future Analysis for Companion Diagnostics by Technology - Polymerase Chain Reaction (PCR), Immunohistochemistry (IHC), In Situ Hybridization (ISH), Next-Generation Sequencing (NGS) and Other Technologies - Independent Analysis of Annual Sales in US$ Million for the Years 2022 through 2030 and % CAGR
    • TABLE 109: Rest of Europe 8-Year Perspective for Companion Diagnostics by Technology - Percentage Breakdown of Value Sales for Polymerase Chain Reaction (PCR), Immunohistochemistry (IHC), In Situ Hybridization (ISH), Next-Generation Sequencing (NGS) and Other Technologies for the Years 2023 & 2030
    • TABLE 110: Rest of Europe Recent Past, Current & Future Analysis for Companion Diagnostics by Indication - Oncology, Neurology and Other Indications - Independent Analysis of Annual Sales in US$ Million for the Years 2022 through 2030 and % CAGR
    • TABLE 111: Rest of Europe 8-Year Perspective for Companion Diagnostics by Indication - Percentage Breakdown of Value Sales for Oncology, Neurology and Other Indications for the Years 2023 & 2030
    • TABLE 112: Rest of Europe Recent Past, Current & Future Analysis for Companion Diagnostics by End-Use - Pharmaceutical & Biopharmaceutical Companies, Reference Laboratories, CROs and Other End-Uses - Independent Analysis of Annual Sales in US$ Million for the Years 2022 through 2030 and % CAGR
    • TABLE 113: Rest of Europe 8-Year Perspective for Companion Diagnostics by End-Use - Percentage Breakdown of Value Sales for Pharmaceutical & Biopharmaceutical Companies, Reference Laboratories, CROs and Other End-Uses for the Years 2023 & 2030
  • ASIA-PACIFIC
    • Companion Diagnostics Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Asia-Pacific for 2023 (E)
    • TABLE 114: Asia-Pacific Recent Past, Current & Future Analysis for Companion Diagnostics by Product & Service - Assay kits & Reagents and Software & Services - Independent Analysis of Annual Sales in US$ Million for the Years 2022 through 2030 and % CAGR
    • TABLE 115: Asia-Pacific 8-Year Perspective for Companion Diagnostics by Product & Service - Percentage Breakdown of Value Sales for Assay kits & Reagents and Software & Services for the Years 2023 & 2030
    • TABLE 116: Asia-Pacific Recent Past, Current & Future Analysis for Companion Diagnostics by Technology - Polymerase Chain Reaction (PCR), Immunohistochemistry (IHC), In Situ Hybridization (ISH), Next-Generation Sequencing (NGS) and Other Technologies - Independent Analysis of Annual Sales in US$ Million for the Years 2022 through 2030 and % CAGR
    • TABLE 117: Asia-Pacific 8-Year Perspective for Companion Diagnostics by Technology - Percentage Breakdown of Value Sales for Polymerase Chain Reaction (PCR), Immunohistochemistry (IHC), In Situ Hybridization (ISH), Next-Generation Sequencing (NGS) and Other Technologies for the Years 2023 & 2030
    • TABLE 118: Asia-Pacific Recent Past, Current & Future Analysis for Companion Diagnostics by Indication - Oncology, Neurology and Other Indications - Independent Analysis of Annual Sales in US$ Million for the Years 2022 through 2030 and % CAGR
    • TABLE 119: Asia-Pacific 8-Year Perspective for Companion Diagnostics by Indication - Percentage Breakdown of Value Sales for Oncology, Neurology and Other Indications for the Years 2023 & 2030
    • TABLE 120: Asia-Pacific Recent Past, Current & Future Analysis for Companion Diagnostics by End-Use - Pharmaceutical & Biopharmaceutical Companies, Reference Laboratories, CROs and Other End-Uses - Independent Analysis of Annual Sales in US$ Million for the Years 2022 through 2030 and % CAGR
    • TABLE 121: Asia-Pacific 8-Year Perspective for Companion Diagnostics by End-Use - Percentage Breakdown of Value Sales for Pharmaceutical & Biopharmaceutical Companies, Reference Laboratories, CROs and Other End-Uses for the Years 2023 & 2030
  • REST OF WORLD
    • TABLE 122: Rest of World Recent Past, Current & Future Analysis for Companion Diagnostics by Product & Service - Assay kits & Reagents and Software & Services - Independent Analysis of Annual Sales in US$ Million for the Years 2022 through 2030 and % CAGR
    • TABLE 123: Rest of World 8-Year Perspective for Companion Diagnostics by Product & Service - Percentage Breakdown of Value Sales for Assay kits & Reagents and Software & Services for the Years 2023 & 2030
    • TABLE 124: Rest of World Recent Past, Current & Future Analysis for Companion Diagnostics by Technology - Polymerase Chain Reaction (PCR), Immunohistochemistry (IHC), In Situ Hybridization (ISH), Next-Generation Sequencing (NGS) and Other Technologies - Independent Analysis of Annual Sales in US$ Million for the Years 2022 through 2030 and % CAGR
    • TABLE 125: Rest of World 8-Year Perspective for Companion Diagnostics by Technology - Percentage Breakdown of Value Sales for Polymerase Chain Reaction (PCR), Immunohistochemistry (IHC), In Situ Hybridization (ISH), Next-Generation Sequencing (NGS) and Other Technologies for the Years 2023 & 2030
    • TABLE 126: Rest of World Recent Past, Current & Future Analysis for Companion Diagnostics by Indication - Oncology, Neurology and Other Indications - Independent Analysis of Annual Sales in US$ Million for the Years 2022 through 2030 and % CAGR
    • TABLE 127: Rest of World 8-Year Perspective for Companion Diagnostics by Indication - Percentage Breakdown of Value Sales for Oncology, Neurology and Other Indications for the Years 2023 & 2030
    • TABLE 128: Rest of World Recent Past, Current & Future Analysis for Companion Diagnostics by End-Use - Pharmaceutical & Biopharmaceutical Companies, Reference Laboratories, CROs and Other End-Uses - Independent Analysis of Annual Sales in US$ Million for the Years 2022 through 2030 and % CAGR
    • TABLE 129: Rest of World 8-Year Perspective for Companion Diagnostics by End-Use - Percentage Breakdown of Value Sales for Pharmaceutical & Biopharmaceutical Companies, Reference Laboratories, CROs and Other End-Uses for the Years 2023 & 2030

IV. COMPETITION